The challenge to one-course carboplatin in seminoma clinical stage 1 (English)
- New search for: Dieckmann, K. P.
- New search for: Anheuser, P.
- New search for: Dieckmann, K. P.
- New search for: Anheuser, P.
In:
ANNALS OF ONCOLOGY
;
27
, 8
;
1648-1649
;
2016
-
ISSN:
- Article (Journal) / Print
-
Title:The challenge to one-course carboplatin in seminoma clinical stage 1
-
Contributors:Dieckmann, K. P. ( author ) / Anheuser, P. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 27, 8 ; 1648-1649
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2016-01-01
-
Size:2 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27, Issue 8
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1365
-
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?Rustin, G. J. / Hall, M. R. et al. | 2016
- 1366
-
Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype?McNeish, I. A. et al. | 2016
- 1368
-
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrumGoel, S. / Krop, I. E. et al. | 2016
- 1372
-
A tribute to biologics in advanced colorectal cancer treatmentSobrero, A. et al. | 2016
- 1374
-
Necitumumab in squamous non-small-cell lung cancer: how to move forward?Garrido, P. / Palacios, J. et al. | 2016
- 1376
-
Where next in kidney cancer?Powles, T. et al. | 2016
- 1378
-
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016Dittrich, C. / Kosty, M. / Jezdic, S. / Pyle, D. / Berardi, R. / Bergh, J. / El Saghir, N. / Lotz, J. P. / Österlund, P. / Pavlidis, N. et al. | 2016
- 1382
-
International cancer seminars: a focus on kidney cancerScelo, G. / Hofmann, J. N. / Banks, R. E. / Bigot, P. / Bhatt, R. S. / Cancel-Tassin, G. / Chew, S. K. / Creighton, C. J. / Cussenot, O. / Davis, I. J. et al. | 2016
- 1386
-
ESMO consensus guidelines for the management of patients with metastatic colorectal cancerVan Cutsem, E. / Cervantes, A. / Adam, R. / Sobrero, A. / Van Krieken, J. H. / Aderka, D. / Aranda Aguilar, E. / Bardelli, A. / Benson, A. / Bodoky, G. et al. | 2016
- 1423
-
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in EuropeCherny, N. / Sullivan, R. / Torode, J. / Saar, M. / Eniu, A. et al. | 2016
- 1443
-
Consensus on precision medicine for metastatic cancers: a report from the MAP conferenceSwanton, C. / Soria, J. C. / Bardelli, A. / Biankin, A. / Caldas, C. / Chandarlapaty, S. / de Koning, L. / Dive, C. / Feunteun, J. / Leung, S. Y. et al. | 2016
- 1449
-
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancerMoschetta, M. / George, A. / Kaye, S. B. / Banerjee, S. et al. | 2016
- 1456
-
Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratorySartore-Bianchi, A. / Loupakis, F. / Argilés, G. / Prager, G. W. et al. | 2016
- 1467
-
The impact of the revolution in hepatitis C treatment on hepatocellular carcinomaWirth, T. C. / Manns, M. P. et al. | 2016
- 1474
-
Current management of newly diagnosed acute promyelocytic leukemiaCicconi, L. / Lo-Coco, F. et al. | 2016
- 1482
-
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapyPitt, J. M. / Marabelle, A. / Eggermont, A. / Soria, J. C. / Kroemer, G. / Zitvogel, L. et al. | 2016
- 1492
-
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)Kim, J. M. / Chen, D. S. et al. | 2016
- 1505
-
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trialLindemann, K. / Kristensen, G. / Mirza, M. R. / Davies, L. / Hilpert, F. / Romero, I. / Ayhan, A. / Burges, A. / Rubio, M. J. / Raspagliesi, F. et al. | 2016
- 1511
-
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessmentCalura, E. / Paracchini, L. / Fruscio, R. / DiFeo, A. / Ravaggi, A. / Peronne, J. / Martini, P. / Sales, G. / Beltrame, L. / Bignotti, E. et al. | 2016
- 1519
-
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab†Loibl, S. / Majewski, I. / Guarneri, V. / Nekljudova, V. / Holmes, E. / Bria, E. / Denkert, C. / Schem, C. / Sotiriou, C. / Loi, S. et al. | 2016
- 1525
-
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapyPivot, X. / Marmé, F. / Koenigsberg, R. / Guo, M. / Berrak, E. / Wolfer, A. et al. | 2016
- 1532
-
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somaticWinter, C. / Nilsson, M. P. / Olsson, E. / George, A. M. / Chen, Y. / Kvist, A. / Törngren, T. / Vallon-Christersson, J. / Hegardt, C. / Häkkinen, J. et al. | 2016
- 1539
-
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)Yamazaki, K. / Nagase, M. / Tamagawa, H. / Ueda, S. / Tamura, T. / Murata, K. / Eguchi Nakajima, T. / Baba, E. / Tsuda, M. / Moriwaki, T. et al. | 2016
- 1546
-
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancerJagadeeshan, S. / Subramanian, A. / Tentu, S. / Beesetti, S. / Singhal, M. / Raghavan, S. / Surabhi, R. P. / Mavuluri, J. / Bhoopalan, H. / Biswal, J. et al. | 2016
- 1557
-
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancerSclafani, F. / Brown, G. / Cunningham, D. / Wotherspoon, A. / Tait, D. / Peckitt, C. / Evans, J. / Yu, S. / Sena Teixeira Mendes, L. / Tabernero, J. et al. | 2016
- 1565
-
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)†Michl, M. / Stintzing, S. / Fischer von Weikersthal, L. / Decker, T. / Kiani, A. / Vehling-Kaiser, U. / Al-Batran, S. E. / Heintges, T. / Lerchenmueller, C. / Kahl, C. et al. | 2016
- 1573
-
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancerPaz-Ares, L. / Socinski, M. A. / Shahidi, J. / Hozak, R. R. / Soldatenkova, V. / Kurek, R. / Varella-Garcia, M. / Thatcher, N. / Hirsch, F. R. et al. | 2016
- 1579
-
Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trialKeefe, S. M. / Hoffman-Censits, J. / Cohen, R. B. / Mamtani, R. / Heitjan, D. / Eliasof, S. / Nixon, A. / Turnbull, B. / Garmey, E. G. / Gunnarsson, O. et al. | 2016
- 1585
-
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial†Clement, P. M. / Gauler, T. / Machiels, J. P. / Haddad, R. I. / Fayette, J. / Licitra, L. F. / Tahara, M. / Cohen, E. E. / Cupissol, D. / Grau, J. J. et al. | 2016
- 1594
-
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer†Argiris, A. / Bauman, J. E. / Ohr, J. / Gooding, W. E. / Heron, D. E. / Duvvuri, U. / Kubicek, G. J. / Posluszny, D. M. / Vassilakopoulou, M. / Kim, S. et al. | 2016
- 1601
-
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE studySuzuki, K. / Yamanaka, T. / Hashimoto, H. / Shimada, Y. / Arata, K. / Matsui, R. / Goto, K. / Takiguchi, T. / Ohyanagi, F. / Kogure, Y. et al. | 2016
- 1607
-
Factors associated with depression and anxiety symptoms in family caregivers of patients with incurable cancer†Nipp, R. D. / El-Jawahri, A. / Fishbein, J. N. / Gallagher, E. R. / Stagl, J. M. / Park, E. R. / Jackson, V. A. / Pirl, W. F. / Greer, J. A. / Temel, J. S. et al. | 2016
- 1612
-
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patientsPatel, J. D. / Pereira, J. R. / Chen, J. / Liu, J. / Guba, S. C. / John, W. J. / Orlando, M. / Scagliotti, G. / Bonomi, P. D. et al. | 2016
- 1619
-
The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortiumHashim, D. / Sartori, S. / Brennan, P. / Curado, M. P. / Wünsch-Filho, V. / Divaris, K. / Olshan, A. F. / Zevallos, J. P. / Winn, D. M. / Franceschi, S. et al. | 2016
- 1625
-
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial†Eigentler, T. K. / Gutzmer, R. / Hauschild, A. / Heinzerling, L. / Schadendorf, D. / Nashan, D. / Hölzle, E. / Kiecker, F. / Becker, J. / Sunderkötter, C. et al. | 2016
- 1633
-
How to report toxicity associated with targeted therapies?Cabarrou, B. / Boher, J. M. / Bogart, E. / Tresch-Bruneel, E. / Penel, N. / Ravaud, A. / Escudier, B. / Mahier Ait-Oukhatar, C. / Delord, J. P. / Roché, H. et al. | 2016
- 1638
-
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapiesCirkel, G. A. / Weeber, F. / Bins, S. / Gadellaa-van Hooijdonk, C. G. / van Werkhoven, E. / Willems, S. M. / van Stralen, M. / Veldhuis, W. B. / Ubink, I. / Steeghs, N. et al. | 2016
- 1644
-
Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathwaysDoherty, M. / Metcalfe, T. / Guardino, E. / Peters, E. / Ramage, L. et al. | 2016
- 1647
-
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baselineRamanathan, R. K. / Korn, R. L. / Chiorean, E. G. / Liu, H. / Von Hoff, D. D. et al. | 2016
- 1647
-
Significance of the prognostic stratification of extranodal extension in colorectal cancerLuchini, C. / Nottegar, A. / Pea, A. / Solmi, M. / Stubbs, B. / Capelli, P. / Sergi, G. / Manzato, E. / Fassan, M. / Wood, L. D. et al. | 2016
- 1648
-
The challenge to one-course carboplatin in seminoma clinical stage 1Dieckmann, K. P. / Anheuser, P. et al. | 2016
- 1649
-
Anti-PD-1-associated organizing pneumonia in a responding melanoma patientFiset, P. O. / Shapera, S. / Butler, M. O. / Tsao, M. S. et al. | 2016
- 1650
-
Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?Paydas, S. et al. | 2016
- 1651
-
Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blockerDa Silva, F. / Thomas-Schoemann, A. / Huillard, O. / Goldwasser, F. / Blanchet, B. et al. | 2016
- 1652
-
Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buysevan Halteren, H. K. et al. | 2016
- 1653
-
Response to the letter to the editor ‘Reply to “Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents” by H. K. van Halteren’Saad, E. D. / Buyse, M. et al. | 2016